Memorial Sloan Kettering Cancer Center | New York, NY - June 13, 2020
(Co-hosted by Memorial Sloan Kettering Cancer Center)
Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals 2019. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care.
Date: June 13, 2020
Time: 9:00am – 11:00am EST
Format: Virtual Zoom Webinar
What do I need to know about the risk of reoccurrence after surgery? Edmund Bartlett, MD
This session will discuss which melanomas are likely to come back after treatment. We will cover where in the body melanomas return, how recurrence is typically found, and how this information guides follow-up and treatment recommendations.
Do I need to do any other treatment after surgery? Allison Betof Warner, MD, PhD
After surgery, many patients who have melanoma identified in the lymph node are eligible for additional therapy to minimize the risk of recurrence. This presentation will highlight who may benefit from therapy after surgery. We will also discuss the risks and benefits of this approach.
How could radiation therapy help me? Christopher A. Barker, MD
Radiation therapy may be helpful to some melanoma patients in certain situations. In this presentation, when, where, why and how radiation therapy may be helpful for melanoma patients will be discussed. In addition, novel approaches and clinical studies at MSKCC using radiation therapy for melanoma patients will be highlighted.
How do diet and exercise influence outcomes? Allison Betof Warner, MD, PhD
Observational studies suggest that physical activity and exercise are associated with reductions in the development and progression of several of cancer. We will discuss how diet and exercise may affect quality of life as well as efficacy and tolerability of therapy for melanoma.
How do I know if a clinical trial is right for me? Michael A. Postow, MD
Clinical trials offer the potential for patients to access new approaches to treat melanoma. We will discuss important information about how these clinical trials work and how best to discuss participation with your treatment team.
Audience Q&A, all panelists, including Jennifer L. Hay, PhD
Audience members are encouraged to submit questions for the panel, including Dr. Jennifer Hay who is a clinical health psychologist with a focus on helping patients and families cope with distress, uncertainty, and decision making in the context of melanoma treatment and survivorship. She works closely with MSK oncologists, surgeons, and dermatologists to help patients navigate the many psychosocial challenges they may face as they work towards their recovery. Her research involves identifying strategies to improve quality of life, decision making, and prevention in the melanoma context.